Reviews/GLP-1 Receptor Agonists/Tirzepatide has better ocular safety
Safety · GLP1-SAF-06 · v2
Across this corpus, several studies point in the same direction: tirzepatide tends to show fewer eye-related safety signals than semaglutide. In adverse-event reporting databases, semaglutide carries strong signals for optic-nerve damage, diabetic retinopathy, and retinal detachment and bleeding, while tirzepatide is flagged mainly for retinopathy alone [2], and a large cohort found tirzepatide linked to lower rates of retinopathy, macular edema, bleeding or detachment, and optic-nerve damage than other similar drugs [9]. However, the one study that compared tirzepatide directly against semaglutide for eye outcomes found no difference between them [8]. The supporting evidence mostly compares tirzepatide to a whole drug class rather than to semaglutide specifically, and the reporting-database studies can be skewed because semaglutide has been on the market much longer and its eye risk is well publicised. One study also found tirzepatide itself raised the odds of advanced retinopathy [4]. The direction favours tirzepatide, but the specific comparison the claim makes is not firmly settled.
The pharmacovigilance papers lean toward tirzepatide: [2] shows semaglutide with significant signals for ischemic optic neuropathy, diabetic retinopathy, and retinal/vitreous detachment and hemorrhage while tirzepatide was significantly associated only with diabetic retinopathy, and [3] and [5] both rank tirzepatide's retinopathy signal below semaglutide's. The largest cohort [9] (102,590 per arm) found tirzepatide associated with lower risk of diabetic retinopathy, macular edema, vitreous hemorrhage/retinal detachment, vision-saving interventions, and NAION (HR 0.45, 95% CI 0.27-0.86) versus non-GIP GLP-1 RAs, the only included paper covering both retinal and optic-nerve endpoints. Against this, [8] directly compared tirzepatide and semaglutide (25,060 matched pairs) and found no differences across its ocular outcomes, and [4] found tirzepatide independently associated with incident proliferative diabetic retinopathy (OR 2.15, 95% CI 1.24-3.74). The contested point: The division is between a consistent directional lean from indirect and class comparisons ([2], [3], [5], [9]) and the single direct tirzepatide-versus-semaglutide ocular comparison [8], which found no difference. It is further unsettled by a within-class harm signal for tirzepatide [4] and by the fact that [8]'s endpoints are cataracts, visual disturbance and dry eye rather than the retinal and optic-nerve events the claim names.
All 16 papers behind this claim with their DOIs and what each does to it, the panel’s arbitration, the evidence gap map and the open research questions. Free, and sent to your inbox.
We’ll also send you other claims from GLP-1 Receptor Agonists, one at a time, and tell you when a release or a pivotal trial changes a grade. Unsubscribe by replying.
One reviewer's only job is to attack the finding. The challenges below were weighed before the grade was set.
The only direct head-to-head of tirzepatide vs semaglutide on ocular outcomes [8] found no differences, directly contradicting the strong form of the claim; its endpoints (cataracts, oculomotor, visual disturbance, dry eye) are not even the retinal/optic-nerve events the claim names, so it neither confirms nor specifically refutes that sub-claim.
The claim is specifically versus semaglutide, but the supportive cohort [9] compares tirzepatide to the non-GIP GLP-1 RA class, [3] and [5] to 'GLP-1RA', and [7] to lifestyle intervention — none isolate semaglutide, so the comparator does not match the claim.
Where it remains uncertain. The only direct tirzepatide-versus-semaglutide ocular comparison found no differences [8], and tirzepatide itself was linked to increased incident proliferative diabetic retinopathy [4].
Aleatory
Optic-nerve and advanced retinal events are infrequent; [4]'s incident PDR rests on small counts (33 vs 17), widening uncertainty around any between-drug difference.
Epistemic
The only direct tirzepatide-vs-semaglutide study [8] measured cataracts, visual disturbance and dry eye, not the retinal and optic-nerve events the claim names, so the specific comparison is unmeasured.
The load-bearing papers from a corpus of 16, each classified by what it does to the claim. Every DOI is taken from the corpus the claim was graded on.
Shows semaglutide carries strong optic-nerve and retinal signals; tirzepatide flagged only for DR in FAERS — supports directional claim
“However, tirzepatide was only significantly associated with DR in FAERS.”
Panel auditInternal validity: low · scope of inference: Relative reporting-rate signals for ocular adverse events across global pharmacovigilance databases.Key limitations: disproportionality not incidence · no direct drug-to-drug test · reporting bias · confounding by indication
Tirzepatide lower DR risk vs GLP-1RA class (indirect comparator)
“TZP exhibited a similar risk of GI AE and medullary thyroid cancer and a lower risk of most pancreato-biliary AE and diabetic retinopathy vs. GLP-1RA.”
Panel auditInternal validity: low · scope of inference: FAERS reporting of diabetic retinopathy for tirzepatide versus the GLP-1RA class.Key limitations: GLP-1RA class not semaglutide · no optic nerve data · disproportionality only
Counter-signal: tirzepatide independently raises incident proliferative retinopathy odds
“Tirzepatide was significantly associated with new-onset PDR in multivariate analysis after adjustment for established risk factors (OR 2.15 [95% CI 1.24, 3.74], p<0.01).”
Panel auditInternal validity: medium · scope of inference: New-onset and progression of diabetic retinopathy after tirzepatide versus no tirzepatide in type 2 diabetes.Key limitations: no semaglutide comparator · retrospective real-world coding · retinal outcomes only
With no semaglutide comparator, the between-drug claim is not addressed.
Panel auditInternal validity: medium · scope of inference: Tirzepatide versus lifestyle intervention for diabetic retinopathy onset, progression and interventions.Key limitations: comparator is lifestyle not semaglutide · retrospective · 12-month follow-up
4 of 16 papers shown. The full review lists all of them, with the panel’s arbitration →
Claims are graded at each quarterly release, and re-graded between releases only when a pivotal trial lands. Every change is a new version of the claim.
Consistent directional signal favouring tirzepatide is offset by a null direct head-to-head, comparator mismatch, disproportionality bias, and a tirzepatide retinal harm signal, leaving the specific claim genuinely uncertain.
Release 2026-q4 re-graded every claim from its corpus under protocol v0.19. An earlier release's grade is shown for the record; it came from an earlier protocol and is not a movement.
Assumptions that carry weight but are not themselves established.
The panel records the gap that would most move the claim, and the study that would close it.
Direct tirzepatide-vs-semaglutide comparison on retinal and optic-nerve endpoints. The claim's exact contrast is untested in this corpus; [8] compared the two drugs but on cataracts, visual disturbance and dry eye, not retinopathy, NAION or ischemic optic neuropathy. The panel rates this the highest-importance open gap for the claim, and names the study design that would close it: A propensity-matched cohort or trial comparing tirzepatide and semaglutide head-to-head with prespecified diabetic retinopathy, macular edema, vitreous hemorrhage/retinal detachment, and optic-nerve (NAION/ION) endpoints over sustained follow-up.
Open question: Does tirzepatide produce lower rates of retinal and optic-nerve adverse events than semaglutide specifically, rather than versus the GLP-1 RA class? Why it is still open: The only direct ocular comparison [8] found no difference on different endpoints, and the supportive cohort [9] uses a class comparator, so the semaglutide-specific contrast is unestablished.
Priors is a sceptical first reader, not peer review, and not medical advice.
Release 2026-q4 · graded 21 Oct 2026 · protocol v0.19